Solarea Bio Announces Licensing Agreement with ADM

Rhea-AI Summary

On October 19, 2021, Solarea Bio, a biotech firm from Cambridge, MA, announced a technology licensing agreement with ADM (NYSE: ADM). This partnership aims to harness microbial technologies developed by Solarea to address inflammatory conditions like osteoporosis. ADM will explore using these microbes in innovative food and beverage solutions targeting health and wellness. Both companies expressed enthusiasm about the collaboration and its potential to create impactful health solutions. This agreement underscores ADM's commitment to expanding its microbiome strategic platform for growth.

Positive

• Technology licensing agreement with ADM allows validation of Solarea's microbiome discovery platform.
• Potential for new health-focused food and beverage products enhances market opportunities for both companies.
• Partnership aligns with ADM's growth strategy in the microbiome sector.

Negative

• None.

CAMBRIDGE, Mass., Oct. 19, 2021 /PRNewswire/ -- Solarea Bio, a biotech company based in Cambridge, MA that is developing microbial-based solutions to aid human health, today announced it has signed a technology licensing agreement with global nutrition leader ADM (NYSE: ADM).

Global nutrition leader ADM signs microbiome technology licensing agreement with Solarea Bio

Solarea Bio has developed innovative technologies to harness the power of microorganisms to modulate inflammatory processes in conditions such as osteoporosis in humans, leveraging the company's extensive capabilities in data science and microbial product development experience. This new agreement allows ADM to examine the functionality and potential for use of these microbes in new food and beverage solutions designed to support health and wellness.

"ADM is a well-established and respected partner, and this new agreement will help validate our microbial discovery platform and provide an additional path for Solarea technology to enter the market," said Dr. Gerardo V. Toledo, CEO and co-founder of Solarea Bio, Inc. 

"The microbiome is one of ADM's six strategic platforms that are powering ADM's growth, and we're continuing to expand our capabilities and develop the next wave of innovation for consumers who are looking for foods and beverages to support their health and wellness," said Daniel Ramon Vidal, ADM Distinguished Research Fellow in the microbiome field. "We look forward to partnering with Solarea Bio and to leveraging their unique technology and expertise to explore the potential for new nutrition products and solutions."

Toledo continued, "The opportunities to create meaningful improvement in people's lives through the commercialization of our technology are vast. We're glad to be moving into the commercial realm and dedicated to finding paths to market that will make the impact that inspires all of us at Solarea."

About Solarea
Solarea Bio is a biotechnology company based in Cambridge, MA developing new microbiome-based solutions to some of the world's largest health problems. Solarea was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health. Solarea's breakthrough came from the combined efforts of the company's co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods, and their applications in inflammatory processes including the gut-musculoskeletal axis. Solarea Bio: Inspired by Nature, Powered by Science.^™

About ADM
At ADM, we unlock the power of nature to provide access to nutrition worldwide. With industry-advancing innovations, a complete portfolio of ingredients and solutions to meet any taste, and a commitment to sustainability, we give customers an edge in solving the nutritional challenges of today and tomorrow. We're a global leader in human and animal nutrition and the world's premier agricultural origination and processing company. Our breadth, depth, insights, facilities and logistical expertise give us unparalleled capabilities to meet needs for food, beverages, health and wellness, and more. From the seed of the idea to the outcome of the solution, we enrich the quality of life the world over. Learn more at www.adm.com.

Solarea Media Relations
Rachel Raymond
rraymond@solareabio.com
info@solareabio.com

ADM Media Relations
Jackie Anderson
media@adm.com  
312-634-8484

View original content to download multimedia:https://www.prnewswire.com/news-releases/solarea-bio-announces-licensing-agreement-with-adm-301403293.html

SOURCE Solarea Bio

FAQ

What is the recent partnership between ADM and Solarea Bio?

ADM has signed a technology licensing agreement with Solarea Bio to explore microbial-based solutions for health and wellness.

What is the focus of the technology developed by Solarea Bio?

Solarea Bio focuses on microbial technologies that modulate inflammatory processes related to health conditions like osteoporosis.

How does the ADM and Solarea agreement impact the health and wellness market?

The agreement allows for the development of innovative food and beverage solutions aimed at supporting health and wellness.

What date was the ADM and Solarea Bio agreement announced?

The agreement was announced on October 19, 2021.

What is ADM's strategy related to the microbiome?

The microbiome is one of ADM's six strategic platforms aimed at driving growth and innovation.